Department of Endocrinology, Endokrinologikum Frankfurt, Frankfurt/Main, Germany.
Department of Internal Medicine IV, University Hospital of Munich, LMU Munich, Munich, Germany.
Horm Metab Res. 2019 Dec;51(12):792-797. doi: 10.1055/a-1023-4181. Epub 2019 Nov 25.
A lack of vitamin D seems to be related to autoimmune diseases including autoimmune thyroiditis (AIT). This study intends to determine the correlation between improvement of 25-hydroxyvitamin D [25(OH)D] levels and AIT in patients from an outpatient endocrine clinic in Frankfurt, Germany. This study included 933 patients with thyroid peroxidase antibodies (anti-TPO-Ab) ≥34 kIU/l, including most patients with clear AIT due to a concurrent sonographic evidence of reduced echogenicity. We performed clinical evaluation and laboratory analysis at five points in time within two years retrospectively. Due to a high dropout rate within the observation period, we excluded the last two time points from analysis. Data from 933 AIT patients revealed 89% having vitamin D deficiency or insufficiency [25(OH)D <75 nmol/l] with a median 25(OH)D level of 39.7 nmol/l. At baseline, a weak inverse correlation between 25(OH)D and anti-TPO-Ab was observed during winter (r=-0.09, p=0.048*), but not during summer time (p>0.2). We discovered 58 patients having initially a 25(OH)D level < 75 nmol/l (median: 40.2 nmol/l), which improved over time to a 25(OH)D level ≥ 75 nmol/l (median: 83.2 nmol/l, p<0.0005***). Simultaneously, the median anti-TPO-Ab level showed a significant decrease of 25% from 245.8 to 181.3 kIU/l (p=0.036*). A significant reduction of the median anti-TPO-Ab level of 9% was also observed in the control group, which consisted of patients having constantly a 25(OH)D level <75 nmol/l. The result may suggest that in particular patients with 25(OH)D levels < 75 nmol/l benefit from an increase of 25(OH)D levels ≥ 75 nmol/l. Further prospective randomized controlled clinical trials are needed to finally evaluate if vitamin D has immunmodulatory effects in AIT.
维生素 D 缺乏似乎与包括自身免疫性甲状腺炎 (AIT) 在内的自身免疫性疾病有关。本研究旨在确定德国法兰克福门诊内分泌诊所患者 25-羟维生素 D [25(OH)D] 水平改善与 AIT 之间的相关性。该研究纳入了 933 例甲状腺过氧化物酶抗体 (anti-TPO-Ab)≥34 kIU/l 的患者,其中大多数患者由于同时存在超声回声降低的证据而明确患有 AIT。我们在两年内回顾性地在五个时间点进行了临床评估和实验室分析。由于在观察期内高脱落率,我们将最后两个时间点排除在分析之外。来自 933 例 AIT 患者的数据显示,89%的患者存在维生素 D 缺乏或不足 [25(OH)D<75nmol/l],中位 25(OH)D 水平为 39.7nmol/l。在基线时,冬季时观察到 25(OH)D 与抗 TPO-Ab 之间存在微弱的负相关关系(r=-0.09,p=0.048*),但在夏季时则无此相关性(p>0.2)。我们发现最初有 58 例患者的 25(OH)D 水平<75nmol/l(中位数:40.2nmol/l),随着时间的推移,25(OH)D 水平改善至≥75nmol/l(中位数:83.2nmol/l,p<0.0005***)。同时,抗 TPO-Ab 水平的中位数也显著下降了 25%,从 245.8 降至 181.3kIU/l(p=0.036*)。在对照组中,也观察到抗 TPO-Ab 水平的中位数降低了 9%,对照组患者的 25(OH)D 水平始终<75nmol/l。结果表明,维生素 D 缺乏的患者,特别是 25(OH)D 水平<75nmol/l 的患者,可能会从 25(OH)D 水平升高至≥75nmol/l 中获益。还需要进一步的前瞻性随机对照临床试验来最终评估维生素 D 是否对 AIT 具有免疫调节作用。